Signia Therapeutics is a spin-off of Université Claude Bernard Lyon1, that has and will continue to develop a proprietary platform to identify new products for the respiratory tract virus market where new approaches are greatly needed. Signia Therapeutics benefits from well established academic and industrial partnerships of VirPath laboratory, which contribute to significantly de-risking the path to Research and Development, innovation and licensing revenues.
Signia Therapeutics proposes an innovative and versatile platform for antiviral drug discovery and repurposing based on globally targeting the host cell instead of specific viral molecular determinants. This novel proprietary development strategy has already a proven track record and is based on a solid set of proofs of concept. The Company’s strategy is well adapted to the pathogenesis of respiratory acute infections and provides a novel approach for the identification of broad-spectrum effective antivirals. The innovative and proprietary platform will offer the minimization of drug resistance, with significant regulatory and financial benefits compared to the time-consuming and costly process of classical de novo molecule development.
Signia Therapeutics is well positioned with a clinical and preclinical pipeline of antivirals of interest to large and specialty pharma partners and targeted markets. Signia already has a Phase 2b trial fully funded for a product identified through its proprietary platform.
Proofs-of-concept were established, several FDA-approved drugs were validated for new antiviral indication and one clinical trial (FLUNEXT) will start in December 2018 for the evaluation of one very promising antiviral candidate in 300 Flu patients, with final results expected in 2020. This clinical trial is financed by the French Health Ministry. Ongoing programs are currently conducted by Signia Therapeutics and dedicated to the identification and validation of broad-spectrum antiviral compounds against Flu, RSV, hMPV and human Coronaviruses such as MERs-CoV. Three patents covering drugs for the treatment of severe influenza and MERS-CoV are under licensing to Signia Therapeutics.
Société par Actions Simplifiée au capital de 15.000 euros
Siège social : L’Atrium – 43 boulevard du 11 novembre 1918